IRCT20220211053992N19招募中Unknown
In vivo Bioequivalence study of Palbociclib 125 mg capsule manufactured by Sobhan Oncology Pharmaceutical Co. Compared to innovator Product
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 59 years（—）
- 性别
- All
入选标准
- •General Health (in terms of Liver, Heart and Kidney diseases)
- •Age between 18 to 59 years
排除标准
- •History of cardiovascular, liver, and kidney disease
- •Alcohol and drug addiction
- •History of drug allergy
研究者
相似试验
招募中
Unknown
In-vivo Bioequivalence Study of Palbociclib 125 mg Hard Capsules of The Test Drug (PADENZA®, Abidi Pharma, Iran)This study is performed on healthy volunteers and drug concentration in plasma is determined..IRCT20200105046010N112Abidi Pharmaceutical Company24
招募中
Unknown
In-vivo Bioequivalence Study of Palbociclib 125 mg Hard Capsules of The Test Drug (PALBRANCE®, Arena Hayat Danesh, Iran)This study is performed on healthy volunteers and drug concentration in plasma is determined..IRCT20200105046010N116Arena life science24
招募中
Unknown
In-vivo Bioequivalence Study of (IBRACT®, 125 mg Cap., Actero Pharma, Iran)This study is performed on healthy volunteers and drug concentration in plasma is determined..IRCT20200105046010N113Actro Middle East Pharmaceutical Co24
进行中（未招募）
1 期
A study for patients with metastatic breast cancer (hormone receptor-positive, negative HER2 and resistance to non-steroidal aromatase inhibidors) comparing palbociclib + exemestane versus capecitabine.Patients with hormonal receptor positive and HER2 negative MBC who are resistant to prior NSAI therapy.MedDRA version: 19.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2013-003170-27-IEGEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)550
进行中（未招募）
1 期
A study for patients with advanced breast cancer (hormone receptor-positive, negative HER2 and resistance to non-steroidal aromatase inhibidors) comparing palbociclib + exemestane versus capecitabine.EUCTR2013-003170-27-LVGEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)601